【交银国际：首予三生制药(01530.HK)“买入”评级 目标价27港元】智通财经APP获悉，交银国际发布研报称，三生制药(01530.HK)核心大单品长期空间可观，创新研发成果即将集中落地，首予该股“买入”评级，目标价27港元，对应20.7倍2025年市盈率(剔除707
BD首付款影响)和1.4倍2025年市盈增长率。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.